Introduction
============

Colorectal cancer, also called colon cancer, consists of cancerous growths in the colon, rectum and appendix. Colorectal cancer arises from adenomatous polyps in the colon. There are more than one million new cases of colorectal cancer each year in the world, and \~ half of them are fatal (1,2). In China, 130,000 - 160,000 new cases of colorectal cancer are diagnosed each year and 60,000 - 90,000 patients die. Treatment depends on the stage of the cancer (3). Surgery is still the primary treatment. Chemotherapy is also considered depending on the individual patient\'s staging and other underlying causes, especially whether or not it spreads to the lymph nodes (Stage III) (3). In China, treatments for colorectal cancer are surgery and chemotherapy. Most colorectal cancer patients in stages II/III are treated with surgery plus chemotherapy. Recent advances in chemotherapy treatment has led to improvement in the quality of life and survival rate in colorectal cancer patients.

5-Fuorouracil (5-FU) is a widely used anticancer drug for more than 40 years, which can cause severe toxic side effects, including death. 5-FU is also one of the most effective medicines in treating patients diagnosed with colorectal cancer (4-6). The 5-FU is a pyrimidine analog and works through non-competitive inhibition of thymidylate synthase and thus blocks the synthesis of the pyrimidine thymidine, which is a nucleotide required for DNA replication. DPD is a powerful liver enzyme to catabolize \>80 % of the administered 5-FU in liver. About 8% of the population has what is termed DPD deficiency and unable to metaolize 5-FU resulting in toxic side effects because they have a genetic inability to metabolize 5-FU (7-10).

DPD gene is \~950 kb genome, which locates on chromosome 1p22, including a 3 kb coding sequence spanning in 23 exons (11,12). DPD activity is highly variable, influencing the patient\'s response to 5-FU, which could be due to SNP genetic polymorphism (7-9,13-18). The SNPs of DPD cause enzymatic deficiency from partial (3-5% of the population) to complete loss (0.2% of the population) of enzyme activity (7-9,13-19). More than 40 different DPD alleles have been identified (13-19). To date, the respective frequencies of different SNPs and their effects, especially in China, have not been investigated in detail. To improve the treatment for colorectal cancer, especially in China, we selected 5 SNPs of DPD, 14G1A, G1156T, G2194A, T85C and T464A. Sixty patients treated with 5-FU were evaluated to determine the correlation between the SNPs of DPD, DPD activity and the 5-FU toxic side effect.

Materials and methods
=====================

Patients and treatments
-----------------------

Experiments in this study were undertaken with the understanding and written consent of each subject, and such that the study conforms with the Code of Ethics of the World Medical Association. In this study, we screened 98 patients and only selected 60 patients without diarrhea before FOLFOX4 (1) scheme chemotherapy. Sixty colorectal cancer patients, 33 males and 27 females, ages between 39 and 67, were enrolled in August, 2007. They did not have any serious heart, lung, liver, kidney or brain disease, and had \<4.0 x 10^9^/L of WBC (white blood cells), \<100 g/L of HB (haemoglobin), \<100 x 10^9^/L of PLT (platelet) clinically. Diagnosis of colorectal cancer for all patients was confirmed pathologically after surgery. There were 28 patients with poorly differentiated carcinoma, 16 patients with moderately differentiated carcinoma and 16 patients with well differentiated carcinoma. All patients received FOLFOX4 (1) scheme chemotherapy, which was 85 mg/m^2^ of oxaliplatin, 200 mg/m^2^ of calcium folinate and 400 mg/m^2^ of 5-FU intravenously plus 600 mg/m^2^ of 5-FU by syringe pump on day 1; 200 mg/m^2^ of calcium folinate and 400 mg/m^2^ of 5-FU intravenously plus 600 mg/m^2^ of 5-FU by syringe pump on day 2 - 14 for one treatment; at least two treatments/patient and 4 - 6 treatments on the average.

Determination of DPD activity
-----------------------------

Blood samples, which used to get all DPD activities in table [4](#T4){ref-type="table"}, were collected with EDTA treated blood tube at 6:00 am before breakfast two days before FOLFOX4 scheme chemotherapy, centrifuged at 3000 g for 10 min and stored at -80ºC until analysis. In this study we used ratio of dihydrouracil (UH~2~) to uracil (U) to represent blood DPD activity (20). The concentrations of UH~2~ and uracil in plasma were determined by HPLC (high-performance liquid chromatography) using C18 column (300 mm x 4.6 mm, 5μm, Dalian Elite Analytical Instruments Co., Ltd. Dalian, China) at 10ºC, 0.4 ml/min and detected with 204 nm. In this study, UH~2~ and uracil were extracted from 200 μl plasma. Briefly, 200 μl plasma plus 50 μl of 5-BU (5-Bromouracil) at 200μg/ml as internal control were added into a 10 ml tube and mixed by vortex for 30 min. Then, 1.5 ml of extraction buffer \[n-propanol:ether (vol/vol) = 25:75\] was added into the tube, mixed by vortex for 5 min, spun at 3000 g/min for 5 min and collected organic phase. This extraction procedure was repeated once and put two organic phases together. Next, the organic phase was dried at room temperature under nitrogen, re-constituted with 50 μl ddH~2~O, mixed by vortex for 30 s and 20 μl dichloromethane was added into the tube, mixed by vortex for 5 s and spun at 12,000 g/min for 10 min. Twenty μl supernatant were used for HPLC. The spike U/UH~2~ concentrations in 3% of BSA (bovine albumin) were used as a standard as following, 15.625/62.5, 31.25/125, 62.5/250, 125/500, 250/1000, 500/2000 μg/L. UH~2~ was detected at 204 nm. U was detected at 260 nm (21). The sensitivity was 0.01 AuFS (absorbance unit full scale). All other equipments and reagents were purchased from Fuzhou Maxim Biotechnology Technology Development Company (Fuzhou, China). Procedures were followed as described in the manual.

SNP detection
-------------

The genomic DNA from EDTA (ethylenediaminetetraacetic acid) treated peripheral blood samples were extracted using Blood Genome DNA Extraction Kit (Dalian Treasure Biotechnology; Dalian, China). Following TaqMan MGB primers and probes were purchased with plasmid Allele 1 and 2 standards as standard controls from Applied Biosystems (Foster City, CA, USA). For 14G1A, 14G1A-FP-1: TCCTCTGCAAAAATGTGAGAAGG, 14G1A-FP (or RP)-2: GCTTTTCTTTGTCAAAAGGAGACTCA, DPD-85 (T): FAM-ATGCAACTCTGTGTTCCACTTCGGC, DPD-85 (C): awakens (or TET)-CATGCAACTCTGCGTTCCACTTCG; for G2194A, DPD-2194-FP: TGAAAATGTTGATGTGTCTTGCATAG, DPD-2194-RP: CCATATGTAGTTCGCTTTGCAATC, DPD- 2194 (G): FAM-CCAATGGCGTTACAGCCACCAA, DPD- 2194 (A): awakens (or TET)-TGCCAATGGCATTACAGCCACC; for G1156T, DPD-1156-FP: GAACAAACTGCATAGCAACAATTCTC, DPD-1156-RP: TCTCTGTTCTGTTTTGTTTTAGATGGA, DPD-1156 (G): FAM-CAGAAATTCACACTTTT, DPYD-1156 (T): awakens (or TET) CAGAAATTAACACTTTTC; for T464A, DPD-464-FP: AGATATTTGTGCATGGTGATGGTAGT, DPYD-464-RP: TCCAACCTCTGATCTTTGTGTAGGT, DPD-464 (T): FAM-TGCTGCAATCCACCAA, DPD- 464 (A): awakens (or TET) TTGCTGCTATCCACCAA; for T85C: DPD-85-FP: CCTGGCTTTAAATCCTCGAACA, DPD-85-RP: GCAGTTCTTATCAGGATTTCTTTTCC, DPD-85 (T): FAM-ATGCAACTCTGTGTTCCACTTCGGC, DPD-85 (C): awakens (or TET) CATGCAACTCTGCGTTCCACTTCG. The real time PCR assays were performed in an ABI 7300 Real time PCR system using 100 ng DNA sample with TaqMan Universal PCR Master (Applied Biosystems). The conditions used were as follows: 95ºC for 10 minutes, 92ºC for 10 seconds, and 60ºC for 1 minute for 40 cycles.

Toxicity assessment
-------------------

In this study, WHO toxic grading standard for chemotherapy was used (Table [1](#T1){ref-type="table"}) (22). Before starting chemotherapy, patients had a very detailed physical examination and clinical lab testing. After patient received chemotherapy, blood chemistry and hematology was examined every week. Physical examination was also performed every week. Aspartate aminotransferase (AST), alanine aminotrasferase (ALT), blood urea nitrogen (BUN) and creatinine were checked to evaluate functions of liver and kidney every two weeks. We also obtained an electrocardiogram every two weeks. We carried out toxicity assessment depending on all clinical data using WHO toxic grading standard (Table [1](#T1){ref-type="table"}).

Statistical analysis
--------------------

Data analyses employed SPSS 13.0 software (SPSS, Inc, Chicago, IL, USA). Results herein are presented as mean values ± standard error (SEM). Chi squared test, one-way ANOVAs followed by a Tukey test and Mann Withney analysis, were employed as appropriate to determine the statistical significance of differences observed.

Results
=======

Results of toxicity assessment of bone marrow and gastrointestinal reaction are shown in Table [2](#T2){ref-type="table"} based on criteria in Table [1](#T1){ref-type="table"}. About 5-7% of patients did not have bone marrow or gastrointestinal toxicities. There were \~15% of patients with the highest grade (III-IV) of bone marrow toxicity and \~22% of patients with the highest grade (III-IV) of gastrointestinal toxicity.

Next, we examined plasma DPD activity (Fig. [1](#F1){ref-type="fig"}, Table [4](#T4){ref-type="table"}) using liquid HPLC chromatography. It clearly showed that the patients had no or lower toxicity (toxic grades 0, I and II were defined as not severe group herein) when they had higher DPD activity in their plasma and higher toxicity when they had lower DPD activity in their plasma (*p*\< 0.001 by one-way ANOVAs and Mann Withney U = 18.50, two-tailed p\<0.0001 for bone marrow inhibition; *p*\< 0.001 by one-way ANOVAs and Mann Withney U = 149.0, two-tailed p\<0.0115 for gastrointestinal reaction).

To understand the correlation between DPD activity, toxicity of 5-FU and SNPs of DPD, we detected 5 SNPs of DPD, 14G1A, G1156T, G2194A, T85C and T464A, using genomic DNAs from all 60 patients. Characteristics of each SNP are shown in Table [2](#T2){ref-type="table"}. Results of SNPs by real time PCR are shown in Table [3](#T3){ref-type="table"}. All 60 patients were negative for 14G1A and G1156T detection. Six patients (10%) were heterozygous changes for G2194A. Ten patients (\~16.7%) were positive for T85C, whereas 8 patients (\~13.3%) heterozygous changes and 2 patients (\~3.3%) were homozygous changes. For T464A, 2 patients (\~3.3%) were heterozygous changes.

Data in Table [4](#T4){ref-type="table"} demonstrated that there was no gender and age correlation with SNPs of DPD, G2194A, T85C and T464A. Six positive patients for G2194A (Table [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}) were all heterozygous. Four patients had higher DPD activities (\> 3) with corresponding lower toxic side effects (≤ stage II), and two patients had lower DPD activities (\< 3) with corresponding higher toxic side effects (≥stage III), and one patient was also positive for T85C detection. Ten patients (Table [4](#T4){ref-type="table"}) were positive for T85C detection. In eight patients who had heterozygous changes, three patients had lower DPD activities (\< 3) with corresponding higher toxic side effects (≥stage III), and five patients had higher DPD activities (\> 3) with stage I to IV toxic side effects. Two patients for T85C detection (Table [4](#T4){ref-type="table"}) were homozygous with lower DPD activities (\< 3) and higher toxic side effects (≥stage III). Only two patients were positive to the T464A detection, which were heterozygous with lower DPD activity and higher toxic side effects, especially bone marrow inhibition. These two patients were also positive for T85C detection.

Statistical analyses demonstrated that the overall DPD activity was significant lower in SNP positive patients. In this study, the patients with two SNP positive or homozygous changes had markedly lower DPD activity than that of SNP negative patients (*p*\< 0.001 - 0.007 by one-way ANOVAs)(Fig. [2](#F2){ref-type="fig"}A-[2](#F2){ref-type="fig"}D). Fig. [2](#F2){ref-type="fig"}E also demonstrated that the DPD activity was significantly lower in two SNP positive or homozygous patients than that of one SNP positive patients (*p*\< 0.004 by one-way ANOVAs). Fig. [3](#F3){ref-type="fig"} illustrates the comparison of toxic grade differences between SNP positive and SNP negative patients. Fig. [3](#F3){ref-type="fig"} indicates that the toxic grades of bone marrow inhibition or gastrointestinal reaction from SNP positive patients was significantly higher than that of SNP negative patients (*p*\< 0.0005 or 0.0072 by Mann Withney analysis). Table [5](#T5){ref-type="table"} shows that the SNP positive patients with severe toxic grades of bone marrow inhibition or gastrointestinal reaction were significantly higher than that of the SNP negative patients with severe toxic grades of bone marrow inhibition or gastrointestinal reaction (*p*\< 0.0001 or 0.0019 by Chi-square analysis) while no-severe toxic grades were not significantly different.

These data indicated that the DPD activity was significantly lower in the patient with severe toxic grade of bone marrow inhibition or gastrointestinal reaction as well as in the SNP positive patients. Also, the toxic grade was higher in the SNP positive patients. The T464A and homozygous of T85C have been shown to be significantly correlated to the lower DPD activity and higher 5-FU induced bone marrow inhibition. Two positive SNPs, either G2194A, T85C or T464A, in one patient were significantly correlated with severe 5-FU toxic side effects, especially bone marrow inhibition.

Discussion
==========

Recently, many studies demonstrated that DPD could not efficiently metabolize 5-FU due to DPD genomic variation (13-16), such as exon skipping (23), deletion (24) and missense mutation (25-27). The SNP of DPD is one of the major reasons for DPD deficiency. During our clinical practice, it was recognized that 83.3% of 5-FU treated patients had severe side effects resulting in higher risk for the patients and less or no effects of chemotherapy. To overcome this difficulty and predict toxicity before treatment, clinicians have tried to determine if the SNP of DPD could be used as a biomarker to improve clinical treatment. We, however, still understand little about these SNPs, especially in different populations such as the Chinese population.

It was known that \~50% of patients, who had severe toxicity of 5-FU, were genotypically heterozygous or homozygous for known SNPs in the DPD gene (14,28,29). In the present study, we assessed 5 SNPs of DPD gene for 60 colorectal cancer patients to evaluate if these SNPs could be used to predict the possible toxicity of 5-FU before treatment.

Our results demonstrated that lower activity of DPD was significantly correlated to higher 5-FU toxicity, and higher activity of DPD was also significantly correlated to lower 5-FU toxicity (Table [4](#T4){ref-type="table"}, Fig. [1](#F1){ref-type="fig"}), after we screened 5 known SNPs of DPD, 14G1A, G1156T, G2194A, T85C and T464A, in 60 colorectal cancer patients. Results indicated that the SNPs of 14G1A and G2194A were not common SNPs to affect DPD activity in Chinese, although the 14G1A seem to be very common for other populations (Table [2](#T2){ref-type="table"} and [3](#T3){ref-type="table"}) (15,28,30). The frequency of T464A was 3.3%, 10% for G2194A and 16.7% for T85C. Interestingly, the DPD activity was statistically lower in the SNP positive patients while the toxic grade of bone marrow inhibition or gastrointestinal reaction was higher in the SNP positive patients (Tables [4](#T4){ref-type="table"} and [5](#T5){ref-type="table"}, Figs. [2](#F2){ref-type="fig"} and [3](#F3){ref-type="fig"}). Especially, the T464A, homozygous of the T85C or any combination between T464A, G2194 and T85C were highly correlated with the lower DPD activity and the bone marrow inhibition than that for gastrointestinal reaction (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}, Fig. [2](#F2){ref-type="fig"}).

In summary, we have shown that the SNPs of 14G1A and G2194A were not common in Chinese and indicated that these two SNPs could have differential race expression. Furthermore, we have observed that the SNPs of T464A, homozygous of the T85C or combination of T464A, G2194 and T85C can be used as stronger biomarkers to predict 5-FU toxicity for Chinese population, especially for the bone marrow inhibition (\~5%). To further confirm the clinical value of these three SNPs, we need to screen more patients in order to use these SNPs as a clinical marker to prevent the risk of the 5-FU toxicity before treatment.
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![Comparisons of DPD activities between no severe (grades 0, I and II) and severe (grades III and IV) toxic groups. A. Bone marrow inhibition. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 4.292, lower 95% CI = 4.092, upper 95% CI = 4.492, *p*\<0.001 by one-way ANOVAs and Mann Withney U = 18.50, two-tailed *p*\<0.0001). B. Gastrointestinal reaction. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 4.050, lower 95% CI = 3.816, upper 95% CI = 4.284, *p*\<0.001 by one-way ANOVAs and Mann Withney U = 149.0, two-tailed *p*\<0.0115).](ijmsv10p0894g01){#F1}

![Comparisons of DPD activities between various groups. A. Between SNP negative and SNP positive. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 3.125, lower 95% CI = 2.692, upper 95% CI = 3.559, *p*\<0.001 by one-way ANOVAs and Mann Withney U = 70.0, two-tailed *p*\<0.0001). B. Between SNP negative and two SNPs plus homozygous. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 4.177, lower 95% CI = 3.966, upper 95% CI = 4.388, *p*\<0.001 by one-way ANOVAs and Mann Withney U = 4.0, two-tailed *p*\<0.0014). C. Between SNP negative and T85C positive. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 3.467, lower 95% CI = 2.737, upper 95% CI = 4.196, *p*\<0.006 by one-way ANOVAs and Mann Withney U = 34.0, two-tailed *p*\<0.0033). D. Between SNP negative and G2194A positive. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 3.414, lower 95% CI = 2.570, upper 95% CI = 4.258, *p*\<0.007 by one-way ANOVAs and Mann Withney U = 36.0, two-tailed *p*\<0.014). E. Between one SNP and two SNPa plus homozygous. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 2.253, lower 95% CI = 1.886, upper 95% CI = 2.619, *p*\<0.004 by one-way ANOVAs and Mann Withney U = 3.0, two-tailed *p*\<0.0157).](ijmsv10p0894g02){#F2}

![Comparison of toxic grades between SNP positive and SNP negative patients. A. Comparison of toxic grade of bone marrow inhibition. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 2.667, lower 95% CI = 2.087, upper 95% CI = 3.246, two-tailed *p*\<0.0005 by Mann Withney analysis and Mann Withney U = 158.5). B. Comparison of toxic grade of gastrointestinal reaction. The data shown are mean values ± SD. Differences between two groups are significant (Mean = 2.533, lower 95% CI = 1.946, upper 95% CI = 3.120, two-tailed *p*\<0.0005 by Mann Withney analysis and Mann Withney U = 196.5).](ijmsv10p0894g03){#F3}

###### 

Criteria of bone marrow toxicity and gastrointestinal toxicity used in current study [@B29].

                              Grades                                                                   
  --------------------------- --------- ------------ -------------------- ---------------------------- ----------------------
  Bone marrow inhibition                                                                               
  HB (g/L)                    ≥110      95-109       80-94                65-79                        \<65
  WBC (x10^9^/L)              ≥4.0      3.0-3.9      2.0-2.9              1.0-1.9                      1.0
  PLT (x10^9^/L)              \>100     75-99        50-74                25-49                        \<25
  Gastrointestinal reaction                                                                            
  AST                         ≤1.25xN   1.26-2.5xN   2.6-5xN              5.1-10.0xN                   \>10xN
  Nausea and vomiting         None      Nausea       Transient vomiting   Vomiting requiring therapy   Intractable vomiting

Note: HB, hemoglobin; WBC. White blood cells; PLT, platelets; N, normal (5 - 40 IU/L).

###### 

Characteristics of 5 SNPs of DPD used in this study in the literature.

  Mutation   Exon   Protein                     Frequency (%)   Consequence                                International code   Reference
  ---------- ------ --------------------------- --------------- ------------------------------------------ -------------------- -----------
  14G1A      14     Del(exon 14)                1.5             No expression                              rs1801267            15,28.29
  G1156T     11     E386Ter                     NA              Nonsense, truncated protein, no activity   rs1333728            29,31
  G2194A     18     V732I                       5               Expression↓                                rs1801160            29
  T85C       2      C29R                        29              Unclear                                    rs1801265            32,33
  T464A      5      stop codon in the protein   0.2             Expression↓                                rs666523971          34

###### 

Summary of 5 SNPs of DPD in 60 patients with colorectal cancer.

           Wild type   Heterozygous (genotype frequency)   Homozygous (genotype frequency)   \% of SNP
  -------- ----------- ----------------------------------- --------------------------------- -----------
  14G1A    60          0                                   0                                 0
  G1156T   60          0                                   0                                 0
  G2194A   54          6 (10%)                             0                                 10
  T85C     50          8 (13.3%)                           2 (3.3%)                          16.7
  T464A    58          2 (3.3%)                            0                                 3.3

###### 

Summary of all 60 cases.

  Case   Gender   Age   Diarrhea   BMI     GIR   DPD activity   G2194A   T85C   T464A   
  ------ -------- ----- ---------- ------- ----- -------------- -------- ------ ------- -----
                        Before     After                                                
  1      M        68    No         No      IV    IV             2.57            C/C     T/A
  2      M        63    No         No      IV    IV             2.02            C/C     
  3      F        47    No         No      IV    III            2.19     G/A    T/C     
  4      F        46    No         No      IV    II             2.23            T/C     T/A
  5      F        42    No         No      I     I              3.92            T/C     
  6      F        40    No         No      II    III            3.65            T/C     
  7      M        67    No         No      II    III            3.87            T/C     
  8      M        50    No         No      II    II             3.64            T/C     
  9      F        50    No         No      III   III            3.65            T/C     
  10     M        67    No         No      III   IV             2.07            T/C     
  13     M        59    No         No      I     I              4.48     G/A            
  11     F        40    No         No      II    II             3.23     G/A            
  12     M        61    No         No      II    II             3.46     G/A            
  14     M        58    No         I       III   I              3.30     G/A            
  15     F        65    No         No      III   III            2.60     G/A            
  24     M        49    No         No      0     I              5.23                    
  28     M        47    No         No      0     0              5.03                    
  29     M        54    No         No      0     I              4.23                    
  16     F        52    No         No      I     II             4.78                    
  20     M        55    No         No      I     III            5.80                    
  21     F        44    No         No      I     0              5.47                    
  22     M        50    No         No      I     I              3.96                    
  23     F        41    No         No      I     0              3.98                    
  25     F        50    No         No      I     I              3.98                    
  26     F        43    No         No      I     II             4.79                    
  30     M        64    No         No      I     III            5.67                    
  31     F        48    No         No      I     I              5.16                    
  32     M        63    No         No      I     II             4.01                    
  17     F        52    No         No      II    0              4.12                    
  18     F        52    No         I       II    0              2.85                    
  19     M        39    No         No      II    II             4.63                    
  27     F        67    No         No      II    I              4.84                    
  33     M        50    No         No      II    II             5.02                    
  34     M        49    No         No      II    II             3.78                    
  35     M        60    No         No      II    II             4.28                    
  36     M        39    No         No      II    II             4.03                    
  37     F        51    No         No      II    II             2.95                    
  38     M        49    No         No      II    II             4.21                    
  39     M        67    No         No      II    II             4.49                    
  40     M        59    No         No      II    II             3.72                    
  41     F        56    No         No      II    II             4.42                    
  43     M        48    No         No      II    II             3.91                    
  44     M        63    No         No      II    II             5.62                    
  45     M        58    No         No      II    II             4.21                    
  46     M        51    No         I       II    II             3.69                    
  47     F        48    No         No      II    II             4.68                    
  48     F        56    No         No      II    II             5.22                    
  49     F        52    No         No      II    II             4.58                    
  50     F        58    No         No      II    II             4.28                    
  51     F        62    No         No      II    II             4.30                    
  52     F        57    No         No      II    II             4.27                    
  53     M        52    No         I       II    II             4.33                    
  54     F        59    No         No      II    II             4.62                    
  55     M        61    No         No      II    II             4.88                    
  56     M        60    No         No      II    II             4.57                    
  57     F        58    No         No      II    II             3.60                    
  58     M        51    No         No      II    II             3.99                    
  59     M        51    No         No      II    IV             2.52                    
  60     F        58    No         No      II    II             3.85                    
  42     F        45    No         No      III   II             3.49                    

Note: M, male; F, female; BMI, bone marrow inhibition; GIR, gastrointenstinal reaction. Before: before FOLFOX4 chemotherapy; Aftr: after FOLFOX4 chemotherapy.

###### 

Comparisons between numbers of SNP and toxic grades.

  -------------------------------------------------- ---------------------------------------- --------
                                                     **Grade of bone marrow toxicity**        
  **I - II**                                         **III - IV**                             
  No. of patients had one SNP                        7                                        5
  No. of patients had two SNPs                       0                                        3
  No. of patients had no SNP                         44                                       1
  Chi-square analysis between +SNP and -SNP groups                                            
  Chi-square                                         2.205                                    14.38
  Odds ratio                                         0.4773                                   24.00
  p                                                  0.4773                                   0.0001
                                                                                              
                                                     **Grade of gastrointestinal toxicity**   
  **I - II**                                         **III - IV**                             
  No. of patients had one SNP                        6                                        6
  No. of patients had two SNPs                       1                                        2
  No. of patients had no SNP                         42                                       3
  Chi-square analysis between +SNP and -SNP groups                                            
  Chi-square                                         1.922                                    9.669
  Odds ratio                                         0.500                                    8.00
  p                                                  0.1656                                   0.0019
  -------------------------------------------------- ---------------------------------------- --------
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